Inhibiting the angiogenic process is a clever method of cancer care. Over the last decade,
some antiangiogenic compounds have been developed and approved for cancer treatment …

Most patients with non-small cell lung cancer (NSCLC) present with advanced disease
requiring systemic chemotherapy. Treatment with the antiangiogenic agent bevacizumab in …

Pemetrexed, a new cytotoxic agent, is a potent inhibitor of thymidylate synthetase and other
folate-dependent enzymes. Firstly, pemetrexed was approved in combination with cisplatin …

BACKGROUND: Vascular endothelial growth factor (VEGF) is a key mediator of
angiogenesis. Solid tumors, including non-small cell lung cancer (NSCLC), are dependent …

Platinum doublets are the recommended standard first-line chemotherapy for stage IIIB/IV
non–small-cell lung cancer (NSCLC). As efficacy outcomes associated with currently …

Angiogenesis plays an important role in tumor metastasis and progression, and thus
inhibiting angiogenesis is a promising strategy for treatment of cancer. However, tumor …

背景与目的: 晚期非小细胞肺癌(non-small cell lung cancer, NSCLC) 患者多程治疗失败后,
目前尚无标准的化疗方案. 本研究旨在观察贝伐单抗联合化疗治疗晚期NSCLC …

Standard platinum-based chemotherapy combinations for advanced non–small-cell lung
cancer (NSCLC) have reached a plateau in terms of the survival benefit they offer for …

Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases.
Patients with NSCLC often have an advanced disease at the time of diagnosis, with a 1-year …

BACKGROUND: Oxaliplatin has less haematological toxicity than cisplatin and carboplatin.
The combination of pemetrexed, oxaliplatin and bevacizumab appeared well tolerated and …